FDA Approves Jascayd, First New IPF Drug in Over a Decade
Boehringer Ingelheim has secured FDA approval for Jascayd (nerandomilast), an oral, first-in-class preferential PDE4B inhibitor for adults with idiopathic...
Jon Napitupulu
Novo Nordisk’s MASH Breakthrough: Acquires Akero Therapeutics
Novo Nordisk has agreed to acquire Akero Therapeutics for $54 per share in cash, or roughly $4.7 billion at...
Announcing Nilo Therapeutics: $101M for Immune Disease Drugs
Nilo Therapeutics has closed a $101 million Series A and named Kim Seth as chief executive officer and board...
EU Patent Office Approves ARS Pharma’s Neffy Nasal Spray
ARS Pharmaceuticals secured a significant intellectual property win in Europe, with the European Patent Office’s Opposition Division upholding all...
Lexicon’s New Focus: Addressing Gaps in Chronic Pain Policy
Lexicon Pharmaceuticals convened a policy roundtable in Washington, DC, centered on expanding federal support for non-opioid pain treatments. The...
Abeona & Children’s Hospital CO Open New Gene Therapy Center
Abeona Therapeutics has activated Children’s Hospital Colorado as a qualified treatment center for Zevaskyn (prademagene zamikeracel), the first FDA-approved...
Nilo Therapeutics Launches with $101M for Immune Disease
Nilo Therapeutics has launched with a $101 million Series A to develop drugs that modulate neural circuits to restore...
Revolutionary Tech for Disease Diagnosis Arrives in Newcastle
Newcastle University has partnered with Curium to establish a PET radiopharmaceutical manufacturing site in Newcastle, expected to be operational...
Zenas & InnoCare Announce Promising Autoimmune Drug Deal
Zenas Biopharma has secured a global license from InnoCare Pharma to develop and commercialize orelabrutinib for multiple sclerosis and...
New Partnership Accelerates Drug Development for Innovators
Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions have launched an integrated CMC partnership to deliver end-to-end...